Intelligence Β· Clinical Pipeline

First People's Hospital Pipeline

All ClinicalTrials.gov programs at First People's Hospital β€” phase, modality, and trial IDs.

Programs
1,136

Quick answer

First People's Hospital has 1,136 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

  1. Cohort A will receive an initial load dose of 8mg/kg and a maintenance dose of 6mg/kg intravenously on the first day of every three weeks for a total of 4 doses

    The First People's Hospital of Lianyungang

    HER2 Positive Breast Cancer

    approved small molecule active

    1 trial
  2. Combination of antiplatelet drugs and anticoagulants for at least one month

    The First People's Hospital of Lianyungang

    Acute Myocardial Infarction

    approved small molecule active

    1 trial
  3. Dabigatran Etexilate

    The First People's Hospital of Lianyungang

    Atrial Fibrillation

    approved small molecule active

    1 trial
  4. Dapagliflozin 10 MG

    The First People's Hospital of Lianyungang

    Type 2 Diabetes Mellitus

    approved small molecule active

    1 trial
  5. Daphnetin

    The First People's Hospital of Lianyungang

    Lower Extremity Lymphedema

    approved small molecule active

    1 trial
  6. Dental foam "Biorepair PERIBIOMA"

    The First People's Hospital of Lianyungang

    Oral Health

    approved small molecule completed

    1 trial
  7. Desmopressin

    The First People's Hospital of Lianyungang

    Patients Undergoing Endoscopic Sinus Surgery

    approved small molecule completed

    1 trial
  8. Dex-Esk

    The First People's Hospital of Lianyungang

    Older Patients

    approved small molecule active

    1 trial
  9. Dexamethasone

    The First People's Hospital of Lianyungang

    Carcinoma, Non-Small-Cell Lung

    approved small molecule terminated

    1 trial
  10. Dexamethasone

    The First People's Hospital of Lianyungang

    Pancreatic Cancer

    approved small molecule active

    1 trial
  11. Dexmedetomidine

    The First People's Hospital of Lianyungang

    Overall Survival

    approved small molecule completed

    1 trial
  12. Dexmedetomidine

    The First People's Hospital of Lianyungang

    Postoperative Delirium After Living Donor Renal Transplantation

    approved small molecule active

    1 trial
  13. Dexmedetomidine

    The First People's Hospital of Lianyungang

    Renal Function

    approved small molecule active

    1 trial
  14. Dexmedetomidine

    The First People's Hospital of Lianyungang

    Obstructive Sleep Apnea

    approved small molecule completed

    1 trial
  15. Dexmedetomidine

    The First People's Hospital of Lianyungang

    Elderly

    approved small molecule completed

    3 trials
  16. Dexmedetomidine

    The First People's Hospital of Lianyungang

    Older Patients

    approved small molecule active

    1 trial
  17. Dexmedetomidine

    The First People's Hospital of Lianyungang

    Breast Cancer

    approved small molecule completed

    1 trial
  18. Dexmedetomidine-esketamine combination

    The First People's Hospital of Lianyungang

    Obstructive Sleep Apnea

    approved small molecule active

    1 trial
  19. Diane-35 pretreatment

    The First People's Hospital of Lianyungang

    Polycystic Ovary Syndrome

    approved small molecule active

    1 trial
  20. Edaravone dexborneol

    The First People's Hospital of Lianyungang

    Acute Ischemic Stroke

    approved small molecule active

    1 trial
  21. Esketamine

    The First People's Hospital of Lianyungang

    Postpartum Depression

    approved small molecule active

    1 trial
  22. Esketamine

    The First People's Hospital of Lianyungang

    Scoliosis Correction

    approved small molecule active

    1 trial
  23. Esketamine 0.2 mg/kg

    The First People's Hospital of Lianyungang

    Cesarean Delivery

    approved small molecule completed

    1 trial
  24. Esketamine 1

    The First People's Hospital of Lianyungang

    Elderly

    approved small molecule active

    1 trial
  25. Esketamine combined with dexmedetomidine

    The First People's Hospital of Lianyungang

    Dexmedetomidine

    approved small molecule active

    2 trials
  26. Exenatide

    The First People's Hospital of Lianyungang

    Type 2 Diabetes

    approved small molecule active

    1 trial
  27. Flumatinib

    The First People's Hospital of Lianyungang

    Flumatinib

    approved small molecule active

    1 trial
  28. Folic Acid

    The First People's Hospital of Lianyungang

    Hypertension

    approved small molecule active

    1 trial
  29. Fosinopril

    The First People's Hospital of Lianyungang

    Chronic Kidney Disease

    approved small molecule active

    1 trial
  30. Glucagon-like peptide-1 receptor agonist:Semaglutide

    The First People's Hospital of Lianyungang

    Type 2 Diabetes

    approved small molecule active

    1 trial
  31. Glycopyrronium in Combination With Tropisetron

    The First People's Hospital of Lianyungang

    Postoperative Nausea and Vomiting

    approved small molecule completed

    1 trial
  32. Henagliflozin Proline Tablets treatment

    The First People's Hospital of Lianyungang

    Diabetes Type 2

    approved small molecule active

    1 trial
  33. High-dose anrikefon

    The First People's Hospital of Lianyungang

    Laparoscopic Surgery

    approved small molecule active

    2 trials
  34. Honghe Fujie lotion

    The First People's Hospital of Lianyungang

    Bacterial Vaginitis

    approved small molecule active

    1 trial
  35. Hydroxychloroquine Sulfate

    The First People's Hospital of Lianyungang

    Primary IgA Nephropathy

    approved small molecule completed

    1 trial
  36. Hydroxychloroquine Sulfate 200 Mg Tablet

    The First People's Hospital of Lianyungang

    Atrial Fibrillation

    approved small molecule active

    1 trial
  37. ICS/LABA

    The First People's Hospital of Lianyungang

    Asthma

    approved small molecule active

    1 trial
  38. IVC

    The First People's Hospital of Lianyungang

    Proliferative Diabetic Retinopathy

    approved small molecule active

    1 trial
  39. Icodextrin Peritoneal Dialysis Solution

    The First People's Hospital of Lianyungang

    Peritoneal Dialysis

    approved small molecule active

    1 trial
  40. Individual ATG

    The First People's Hospital of Lianyungang

    Hematopoietic Stem Cell Transplantation

    approved small molecule active

    1 trial
  41. Infliximab

    The First People's Hospital of Lianyungang

    Crohn's Diseases

    approved small molecule active

    1 trial
  42. Insulin

    The First People's Hospital of Lianyungang

    Brain Injuries

    approved small molecule active

    1 trial
  43. Insulin

    The First People's Hospital of Lianyungang

    Acute Pancreatitis

    approved small molecule active

    1 trial
  44. Intranasal dexmedetomidine-esketamine

    The First People's Hospital of Lianyungang

    Adenotonsillectomy

    approved small molecule active

    1 trial
  45. Intravenous Immunoglobulins, Human

    The First People's Hospital of Lianyungang

    Guillain-Barre Syndrome

    approved small molecule active

    1 trial
  46. Intravenous thrombolysis + edaravone

    The First People's Hospital of Lianyungang

    Ischemic Stroke

    approved small molecule active

    1 trial
  47. Irinotecan liposomes combined with cisplatin/carboplatin

    The First People's Hospital of Lianyungang

    Neuroendocrine Tumors

    approved small molecule active

    1 trial
  48. Ixazomib

    The First People's Hospital of Lianyungang

    Multiple Myeloma

    approved small molecule completed

    1 trial

Frequently asked questions

How many pipeline programs does First People's Hospital have?

1,136 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This hub lists all published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Data attribution: Data sources Β· All pipeline programs